New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.